PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Negative revenue growth signals a shrinking top line, alarming for Benjamin Graham. Confirm if it’s cyclical or structural before proceeding.
-83.05%
Negative gross profit growth suggests either falling sales or rising direct costs. Benjamin Graham would consider this a fundamental warning sign.
7.21%
EBIT growth 5-10% – Moderate. Peter Lynch might look for ways the firm could optimize costs to boost EBIT further.
7.21%
Operating income growth 5-10% – Moderate. Peter Lynch would evaluate product-level profitability to see if certain segments could accelerate growth.
7.01%
Net income growth 5-10% – Moderate. Philip Fisher would look at whether incremental improvements can accelerate with scale.
8.82%
EPS growth 5-10% – Moderate. Peter Lynch might look at potential for future expansions if the company maintains or increases margins.
8.82%
Diluted EPS growth 5-10% – Moderate. Peter Lynch would see if new product lines or expansions might lift future diluted EPS faster.
0.91%
Share count up to +3% – Slight dilution. Howard Marks would be cautious but might accept it if used for profitable growth investments.
0.91%
Diluted share count up to +3% – Modest dilution. Howard Marks might tolerate it if used for high-ROI projects or strategic acquisitions.
No Data
No Data available this quarter, please select a different quarter.
1.55%
OCF growth 0-5% – Minimal gain. Howard Marks would be cautious about the company’s ability to fund large projects or dividends.
1.40%
FCF growth 0-5% – Slight improvement. Howard Marks would be cautious about cyclical or temporary factors limiting free cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR signals recent top-line contraction per share. Benjamin Graham would be skeptical unless a turnaround is clear.
91.07%
10Y OCF/share CAGR above 15% – Outstanding long-term cash-generation growth. Warren Buffett would check if reinvestment needs remain manageable.
81.18%
5Y OCF/share CAGR above 15% – Very robust mid-term cash expansion. Warren Buffett would check if reinvestment fosters sustainable growth.
13.88%
3Y OCF/share CAGR 10-15% – Strong. Benjamin Graham would verify that product launches or cost controls drive real cash improvements.
98.43%
10Y net income/share CAGR above 15% – Exceptional long-term profit growth. Benjamin Graham would confirm if these gains hold through economic cycles.
78.58%
5Y net income/share CAGR above 15% – Strong mid-term profit growth. Benjamin Graham would check if leverage artificially boosts earnings.
-7.39%
Negative 3Y net income/share CAGR highlights recent bottom-line decay. Benjamin Graham would want clarity on cost vs. revenue drivers for the declines.
109.82%
10Y equity/share CAGR above 12% – Excellent long-term book value compounding. Warren Buffett would see if consistent profits plus moderate payouts drive this growth.
14.99%
5Y equity/share CAGR above 12% – Strong mid-term book value expansion. Warren Buffett would see if steady profits and moderate payout ratios sustain this pace.
-59.15%
Negative 3Y equity/share CAGR means a near-term drop in book value. Benjamin Graham would be cautious unless restructured operations promise a future rebound.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
8.48%
Asset growth 5-10% – Reasonable. Peter Lynch compares with revenue growth to ensure utilization remains high.
19.47%
Book value/share growth above 12% annually – Strong sign of compounding. Warren Buffett verifies if profits or buybacks mainly drive it.
-6.20%
A negative growth rate in debt means deleveraging, often positive for conservative investors. Benjamin Graham confirms it doesn’t restrict needed investments.
-18.94%
A big drop in R&D might boost near-term earnings but risk starving the pipeline. Benjamin Graham sees if the firm is refocusing or if future growth suffers.
28.45%
SG&A growth above 15% – Aggressive expense expansion. Philip Fisher demands a compelling ROI argument for such heavy spending.